Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President

Asahi Kasei Pharma President Yoshikazu Aoki Asahi Kasei Pharma plans to devote resources to the auto-injector formulation of its flagship osteoporosis agent Teribone (teriparatide), but an authorized generic (AG) rollout for the drug’s original version, hit by a generic entry...read more